Vaxcyte (PCVX) News Today $43.81 +0.11 (+0.25%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$43.95 +0.14 (+0.32%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Vaxcyte (NASDAQ:PCVX) Shares Up 4.6% - Time to Buy?October 11 at 4:06 PM | marketbeat.comBank of America Securities Keeps Their Buy Rating on Vaxcyte (PCVX)October 8, 2025 | theglobeandmail.comVaxcyte Signs 15-Year Agreement with PatheonOctober 8, 2025 | theglobeandmail.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8, 2025 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 8, 2025 | marketbeat.comBank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)October 8, 2025 | finance.yahoo.com111 Capital Takes Position in Vaxcyte, Inc. $PCVXOctober 6, 2025 | marketbeat.comWhat Does Wall Street Think About Vaxcyte (PCVX)?September 30, 2025 | insidermonkey.comVaxcyte teams up with Thermo Fisher to ensure future vaccine productionSeptember 30, 2025 | msn.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in ...September 30, 2025 | finance.yahoo.comVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and ServicesSeptember 30, 2025 | globenewswire.comVaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine StudySeptember 30, 2025 | msn.comBanque Pictet & Cie SA Has $2.71 Million Stock Holdings in Vaxcyte, Inc. $PCVXSeptember 27, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Stake Cut by Assenagon Asset Management S.A.September 27, 2025 | marketbeat.comWe're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn RateSeptember 23, 2025 | finance.yahoo.comStrs Ohio Buys Shares of 16,600 Vaxcyte, Inc. $PCVXSeptember 21, 2025 | marketbeat.comHarbor Capital Advisors Inc. Buys 25,303 Shares of Vaxcyte, Inc. $PCVXSeptember 18, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Shares Acquired by Rhumbline AdvisersSeptember 15, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Stock Position Increased by Intech Investment Management LLCSeptember 15, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comThe Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX)September 14, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Neutral RecommendationSeptember 13, 2025 | msn.comVaxcyte initiated with a Neutral at Goldman SachsSeptember 12, 2025 | msn.comTSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than CompellingSeptember 12, 2025 | msn.comWoodline Partners LP Has $41.98 Million Stock Position in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comFred Alger Management LLC Has $844,000 Stake in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comJones Financial Companies Lllp Has $6.27 Million Stock Holdings in Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comAmundi Sells 63,416 Shares of Vaxcyte, Inc. $PCVXSeptember 12, 2025 | marketbeat.comPolar Asset Management Partners Inc. Acquires Shares of 10,004 Vaxcyte, Inc. $PCVXSeptember 9, 2025 | marketbeat.comAlliancebernstein L.P. Sells 75,151 Shares of Vaxcyte, Inc. $PCVXSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $3.53 Million Stake in Vaxcyte, Inc. $PCVXSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVXSeptember 8, 2025 | marketbeat.comVaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comEventide Asset Management LLC Purchases 86,776 Shares of Vaxcyte, Inc. $PCVXSeptember 6, 2025 | marketbeat.comCormorant Asset Management LP Reduces Stock Position in Vaxcyte, Inc. $PCVXSeptember 6, 2025 | marketbeat.comAllostery Investments LP Buys New Position in Vaxcyte, Inc. $PCVXSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Buys New Shares in Vaxcyte, Inc. $PCVXSeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Invests $3.57 Million in Vaxcyte, Inc. $PCVXSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Grows Stake in Vaxcyte, Inc. $PCVXSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Purchases 592,000 Shares of Vaxcyte, Inc. $PCVXSeptember 4, 2025 | marketbeat.comVaxcyte advances VAX-31 infant Phase 2 studySeptember 3, 2025 | msn.comVaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized DoseSeptember 3, 2025 | globenewswire.comVaxcyte, Inc. $PCVX Stock Position Raised by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Shares Purchased by Raymond James Financial Inc.September 2, 2025 | marketbeat.comDriehaus Capital Management LLC Has $40.06 Million Stock Position in Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comRafferty Asset Management LLC Trims Holdings in Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comNorthern Trust Corp Sells 37,045 Shares of Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comWalleye Capital LLC Trims Stock Position in Vaxcyte, Inc. $PCVXAugust 29, 2025 | marketbeat.comComerica Bank Purchases 21,091 Shares of Vaxcyte, Inc. $PCVXAugust 28, 2025 | marketbeat.com100,100 Shares in Vaxcyte, Inc. $PCVX Acquired by Jump Financial LLCAugust 28, 2025 | marketbeat.com Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCVX Media Mentions By Week PCVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.990.75▲Average Medical News Sentiment PCVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼78▲PCVX Articles Average Week Get the Latest News and Ratings for PCVX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vaxcyte and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Genmab A/S News Today Summit Therapeutics News Today Ascendis Pharma A/S News Today Viatris News Today Dr. Reddy's Laboratories News Today Moderna News Today Roivant Sciences News Today QIAGEN News Today Elanco Animal Health News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
